Icahn School of Medicine at Mount Sinai New York, New York
Michael Dolinger will discuss the nuances of managing IBD in childhood, focusing on diagnosis, therapeutic options, treatment monitoring and targets that are specific to pediatric IBD. In this session, you will learn the epidemiology of pediatric IBD, consideration of monogenetic causes of very-early onset IBD, safety and efficacy of approved biologic therapies for children, use of alternative biologic and small molecule therapies in children and their mechanism of action, safety, and efficacy in pediatric IBD, and the role of growth and nutrition play in children with IBD.
This session is supported by a joint educational grant from Janssen Scientific Affairs, LLC and Eli Lilly and Company.
Learning Objectives:
Understand the sequencing of biologic and small molecule therapies in children, including the mechansm and rationale behind the development of targeted IL-23 inhibitors
Evaluate the current efficacy and safety of biologic therapy in children, including anti-TNF therapies, anti-IL-12/23 therapy, anti-integrin therapy, and JAK inhibitors.
Develop personalized treatment strategies for children with IBD focusing on specific targets that are unique to children, including growth and transmural healing, using data-driven decision making